Compare Revvity Inc (RVTY) vs Vanguard Total International Stock Index Fund ETF (VXUS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Revvity Inc vs Vanguard Total International Stock Index Fund ETF — how do they compare? Revvity Inc trades at $124.14 (market cap $14.18B), while Vanguard Total International Stock Index Fund ETF trades at $87.8. The key difference: Revvity Inc pays a 0.22% dividend while Vanguard Total International Stock Index Fund ETF pays none, and Vanguard Total International Stock Index Fund ETF is trading nearer its 52-week high, Revvity Inc nearer its low. Which is the better fit depends on your goals.
| RVTY | VXUS | |
|---|---|---|
Market Cap | $14.18B | — |
Sector | Technology | Sector/Thematic |
52-Week High | $130.94 | $88.41 |
52-Week Low | $82.26 | $72.17 |
Enterprise Value | $16.50B | — |
Dividend Yield | 0.22% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RVTY trades at $127.08, down 2.41% on the day, with a bullish technical signal from moving averages and strong support at $126. The company reported Q2 2026 EPS of $1.41, beating estimates, and raised its full-year outlook, driven by diagnostics strength and improved cash flow. Recent news includes the acquisition of Human Cell Design and the launch of the SuperFlex prenatal screening system.
Outlook is positive with 52% analyst buy ratings and a $135.25 consensus price target, implying ~6% upside. Risks include a premium valuation (P/E 61.1) and execution of growth initiatives. Strong institutional interest, such as Bank of New York Mellon's $78.77 million investment, supports confidence in the stock's trajectory.
VXUS trades at $88.08, down 0.37% on the day, with a bullish technical signal from moving averages and neutral oscillators. The ETF offers broad international stock exposure, excluding U.S. equities, with a low expense ratio of 0.06% as of Vanguard's latest disclosure in 2026. Recent news highlights institutional buying and long-term growth potential amid U.S. market concentration concerns.
Outlook is positive for diversification benefits and valuation discounts relative to U.S. stocks, supported by analyst optimism. Risks include foreign tax credit limitations in IRAs and emerging market volatility. Wall Street sentiment leans bullish due to improved global growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →About Vanguard Total International Stock Index Fund ETF
VXUS is a comprehensive, low-cost ETF that tracks the FTSE Global All Cap ex US Index, providing exposure to over 8,500 stocks in both developed and emerging markets outside the United States. It serves as a foundational building block for international diversification, allowing investors to own a market-cap-weighted slice of the entire non-U.S. investable equity universe in a single vehicle.
Read more on VXUS →
